Navigation Links
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Date:8/24/2009

ABBOTT PARK, Ill., Aug. 24 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received approval from Health Canada for the XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD). XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials. Abbott will launch XIENCE V in Canada immediately.

"XIENCE V is an important next-generation treatment option combining impressive deliverability with demonstrated efficacy and safety," said Guy Leclerc, M.D., FRCPC, FACC, interventional cardiologist and associate professor of research, Centre Hospitalier de l'Universite de Montreal. "With strong, long-term data supporting it, XIENCE V is a welcome addition for treating patients with coronary artery disease."

Cardiovascular disease is the leading cause of death in Canada.(1) Furthermore, 54 percent of all cardiovascular deaths are due to CAD, whereby plaque buildup narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.(1)

The XIENCE V drug coated stent is used to treat CAD by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner over time to help prevent the artery from becoming blocked again following the stent procedure.

"XIENCE V represents a major advancement in the treatment of heart disease, based upon its ease of use and consistently strong performance across all clinical trials. This is why physicians have embraced XIENCE V, making it the market-leading drug eluting stent around the world," said Robert Hance, s
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency
2. Baylor University Economists Call for Different Tack on Health Care Insurance
3. LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidates Inscrybe Healthcare
4. BryanLGH Health System Selects Clinical Xpert From Thomson Reuters to Improve Clinical Quality
5. Mom & Baby Mobile Health Centers Have Become Primary Care Providers Along the Gulf Coast
6. eHealth interventions need to be continuously evaluated
7. Harvard study reveals taxing job-based health benefits would hit working families hardest
8. Symmetry Medical to Present at Thomas Weisel Partners 2009 Healthcare Conference
9. New Study of House Health Reform Bill: Minnesota Faces Over $654 Million in Medicare-Funded Nursing Home Cuts Over Ten Years
10. U.S. Senate Candidate Cheryle Jackson: Public Option Critical to Real Health Care Reform
11. Healthcare: Public Option Mirrors Other Government Insurance Plans

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)....G.Schwade,M.D.announcesthenewlyenhancedCyberKnife...CenterofMiami,( www.cyberknifemiami.com ). ,,...edintensedoseofradiationthatkillscancercellswithno...nlastfrom30minutestoonehour,andisusuallycompletedi...tCenterintheSoutheasternU.S.,theMiamifacilityhasle...
(Date:11/23/2009)... to treatment advances, study finds , , ...ntent of saliva changes as people age, and better ...simple test to diagnose and treat age-related dise...ins numerous proteins that play a role in digestio...ers are trying to find ways to use these proteins ...
(Date:11/23/2009)...the brain is regulated by a peptide known as C3a, ...into nerve cells and is also important for the mig..., reveals new research from the Sahlgrenska Academ...ugh the research has been carried out using mice a... for human beings, which could be given to patient...
(Date:11/23/2009)...partment of Agriculture (USDA) has awarded a two-y...rsity of Minnesota to complete sequencing the geno.... The funding will be used by the Turkey Genome Se...ing using next-generation sequencing platforms, as... functions in the final genome sequence by use of ...
(Date:11/23/2009)...Call/--AnnTaylorStoresCorp.announcedtodaythatitwil...sandGivingcampaign,aholidayfundraisingandawareness...armarksthethirdyearthatAnnTaylor,throughitsANNCARE...mpaignwhereweofferourshoppersanopportunitytohelpsa...hisholidayseason.ClientswhoshopatAnnTaylor,Loft,An...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2
...600 injuries were reported by the US consumer prod...n previously thought and raising concerns. These ...y are the target market for these wheeled shoes. T...crowded malls and playgrounds. Scott Wolfson...
... no good reason to deny insurers access to genetic...bate published in this weeks BMJ. Only if...nformation can we reasonably stop them seeking gen... be able to differentiate premiums according to ve...
...esearch suggests that cannabis, also known as mari...gies and autoimmune disorders that occur when bod... Researchers led by Andreas Zimmer, at the U.... However, the researchers warned that peo...
... on Thursday received 15 million dollars worth of ...nment to bolster its fight against HIV and AIDS, o...ates will provide Zimbabwe with anti-retroviral dr...US government, which has frosty relations with the...
... TATA company, is in negotiations with Prof Vijay ...ttached to the University of Arkansas, to start p... the final stages. The deal is yet to be finalized...ter (HiDEC) and Neurosurgery Research Programme in...
...llion Euro research project, European Lifestyles a...for Europes four regional seas. As part o...rom 28 institutions from 15 European countries, fo...oss-cutting environmental issues: habitat change, ...
Other Medicine News:Health News:1,600 Roller Shoe Injuries Reported 2Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Zimbabwe Receives 15m Dollars of AIDS Drugs from US 2Health News:Titan may Produce Glucose Watches Soon 2Health News:Dire Future Predicted for Europe's 4 Seas 2
(Date:11/23/2009)..., EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRese...M): Feraheme report,thesecondinamulti-phasesyndi...snewIVironproduct,Feraheme,throughthefirstsixmonth...quantitativeinformationfrom50uniqueNephrologistsan...ssesstrialanduseofFeraheme,obstaclestouse,reasonst...
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonTh...studyofitsleadproduct,PRT-201,inend-stagerenaldise...graft(AVG)creation.TheAVGstudyrepresentsProteon,ss...iouslyannouncingtheinitiationofaPhase1/2studyofPRT...sfistula(AVF)creationearlierthisyear.Proteonalsoan...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-...cedthatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagre...ionoftheproposedmergerbetweenAnesivaandArcionThera...ervotescheduledtotakeplaceatthepreviouslyannounced...ecember3,2009at9:00a.m.PSTat400OysterPoint,Suite10...
Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Brown professor continues debate over recovered memory 50995 1Brown professor continues debate over recovered memory 50995 2Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 1Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 2Fewer Shots Could Still Protect Kids From Pneumonia 50989 1Fewer Shots Could Still Protect Kids From Pneumonia 50989 2
... Risk Based on Clinical Data, Preventive Measur...WALTHAM, Mass., July 22 Interleukin Genetics,Inc....nhanced test report,format and information package...test is currently marketed under the brand name Ge...y. The new report will include quantified risk,inf...
...rd Clinical Trial,Service Unit and Epidemiological...generating results of the SEAS trial of ezetimibe ...results from the SHARP and,IMPROVE-IT trials of ez...the relevant regulatory authorities, independently...esting trials (SHARP and IMPROVE-IT) contain about...
Other Medicine Technology:Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3
TME 61 C
TME 60 S
...for traditional Lasik, Epi-Lasik and anterior and ...f rapidly changing technologies and applications i... remains a proven value, offering surgeons a platf... stay abreast of evolving technologies while prote...
...maging device that provides direct cross sectional...d subjective clinical evaluation in the detection ...mages and analyzes macular thickness, the retinal ...est technology for high resolution scans., ,S...
Medicine Products: